Sounds very cryptic, please tell us more.
My understanding is McBee is a deal guy out of Danaher.
The company says the Astra deal is going great. The timing, just before the euro collapse was not.
Mavenir misses right out of the gate, so you have to questions managements due diligence.
They are now up against their debt covenants and needed a waiver for the next couple of quarters. (The upside there is they can't do any more deals.lol)
Their two biggest shareholders are bailing out at two year lows.
Elliott has become a major shareholder. I believe this is the guy (Paul Singer) who was/is suing Argentina and commandeering ships off their coast. I would think if there are management issues he would be a good one to address them.
I'll give you the tangible book value. The $8.84 is actually Yahoo, and includes intangibles. S&P is showing $5.35 at the end of 2014. Your calc from the 6-K looks correct to me.
Obviously, predicting the future is hazardous work. The point of care market for troponin and BNP is large. If the product is half as good as they say and they don't screw it up with the FDA the future should be bright. Add in potential accretive acquisitions and like I said, I'd tend to err on the long side at these prices.
Are we talking about the same stock c75..?
Consensus EPS est's 2015 .48 , 2016 .58 equals 21% growth.
"2. The tangible book value of TRIB is a fraction of its book value that includes goodwill and intangibles. Goodwill and intangibles can be perishable."
Ah, tangible BV by definition excludes intangibles and goodwill. Per S&P tangible BV is $8.84.
EBITDA per the company is: from 2010 to 2014 $17.9 mil, $19.6, $21.7, $22.8, $23.8.
Respectfully, you are full of baloney.
It's trading at 1 times its growth rate on reduced earnings and 1.3 times BV. If it is a growth stock, I'd say it is pretty cheap.
Does the .58 concensus EPS for 2016 include anything for accretive acquisitions? They have $100 mil to do deals. How much Troponin is in it? They could start selling that as soon as early Q2 2016.
I'm not a fan of management, but sometimes things do go right. I'd err on the long side at these prices.
RSI 15, and still no buyers.
Pretty much a value stock at this point, although analyst price targets suggest it is a growth stock.
Anybody talk to IR? Is management concerned at all?
I think that came up in the conference call and the answer was yes, but there is a breakup fee which XPO would have to pay.
Yes, they are exiting their investment. That is what the 22 million share shelf offering was about two weeks ago. So is Terry Matthews the founder.
Elliott Capital has picked up a lot of the shares.
"3rd party involved, that screwed it up as the report said"
Are you talking about the original screw up 9 months ago or something more recent.
I'm expecting, perhaps in error, a press release stating the adjudication process is done and the FDA submission will be filed at the end of September.
"We all know Ichan has been extremely successful.
Jim Chanos has been equally successful .."
Oh really, "equally successful"? Carl may have a quibble or two regarding that statement.
Chanos is great with accounting fraud but much less so with macro and economics.
You are basically spewing consensus at the bottom of the cycle.
"...what makes you think IOC is worth $5 B."
You made a good trade in the low 40's. Don't be a fool and let this opportunity pass you buy in the low 30's.
"Favored clients traded ahead of the upgrade and sold the stock?"
You must not have noticed that the stock spiked over 75 cents to $15.07 on big volume in the first hour of trading yesterday.
Please, tell us your theory on the yesterday's huge volume.
"Finally, preparation of our FDA submission document is at an advanced stage. It essentially awaits the final outcome from the trial data sets to be ready for submission. The company now estimates that the adjudication process will be completed by the end of August ..."
Did they accomplish this or did they screw it up? Anybody know?